Literature DB >> 16531962

Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis.

D N Amarapurka1, A D Amarapurkar, N D Patel, S Agal, R Baigal, P Gupte, S Pramanik.   

Abstract

INTRODUCTION: Nonalcoholic steatohepatitis (NASH) is common cause of chronic liver disease strongly associated with insulin resistance leading to fibrosis. No factors that determine increasing fibrosis have been well recognized. Liver biopsy is considered as gold standard for diagnosis and prognosis of this disease. AIM: To identify independent predictive factors of liver fibrosis in patients of NASH with diabetes.
MATERIAL AND METHODS: During the year 2001 and 2002 total 36 patients of NASH associated with diabetes were included in the study. The diagnosis of NASH was based on 1) presence of steatosis, inflammation and ballooning on liver biopsy 2) Intake of alcohol < 20 gm of ethanol per week 3) Exclusion of other liver diseases. Patients were labeled as diabetic if random glucose was > 200 mg/dL or fasting glucose more than 140 mg/dL on 2 occasion or having documented use of oral hypoglycemic medications or insulin. Clinical and biochemical variables such as age, sex, obesity, hypercholesterolemia, AST, ALT and AST: ALT were examined for predictors of fibrosis using univariate and multiple regression statistical analysis. Obesity was defined as BMI > 30 for both males and females. Hypercholesterolemia was considered when fasting cholesterol level was above 95th percentile of normal on at least 2 occasions. Fibrosis was noted as present or absent on histology.
RESULTS: Of 36 patients 17 were females and 19 males with age range of 25 to 75 years, mean age 50.8 years. Fibrosis was present in 11 (30.5%) and absent in 25 (69.4%) patients. Univariate and multiple correlations co-efficient failed to detect significant association of fibrosis with above mentioned variables. However multiple regression and logistic regression analysis (MLR) detected statistical significance for AST, ALT levels and AST: ALT ratio between fibrosis and no fibrosis in 80.6% patients.
CONCLUSION: There is no definite noninvasive test that helps to predict liver fibrosis however AST, ALT levels and AST: ALT ratio may help to determine the fibrosis in patients of NASH with diabetes in majority of cases.

Entities:  

Mesh:

Year:  2006        PMID: 16531962

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  30 in total

1.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

2.  A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients.

Authors:  Alex Ulitsky; Ashwin N Ananthakrishnan; Richard Komorowski; James Wallace; Sri Naveen Surapaneni; Jose Franco; Kia Saeian; Samer Gawrieh
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

Review 3.  Insulin sensitizers in treatment of nonalcoholic fatty liver disease: Systematic review.

Authors:  Norberto-C Chavez-Tapia; Tonatiuh Barrientos-Gutierrez; Felix-I Tellez-Avila; Francisco Sanchez-Avila; Maria-Antonieta Montano-Reyes; Misael Uribe
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

Review 4.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

5.  Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes.

Authors:  Tomislav Bulum; Branko Kolarić; Lea Duvnjak; Marko Duvnjak
Journal:  Dig Dis Sci       Date:  2011-07-07       Impact factor: 3.199

6.  Sparstolonin B (SsnB) attenuates liver fibrosis via a parallel conjugate pathway involving P53-P21 axis, TGF-beta signaling and focal adhesion that is TLR4 dependent.

Authors:  Diptadip Dattaroy; Ratanesh Kumar Seth; Sutapa Sarkar; Diana Kimono; Muayad Albadrani; Varun Chandrashekaran; Firas Al Hasson; Udai P Singh; Daping Fan; Mitzi Nagarkatti; Prakash Nagarkatti; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Eur J Pharmacol       Date:  2018-09-05       Impact factor: 4.432

Review 7.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

8.  Biochemical Profile of Nonalcoholic Fatty Liver Disease Patients in Eastern India with Histopathological Correlation.

Authors:  Manorama Swain; Preetam Nath; Prasant Kumar Parida; Jimmy Narayan; Pradeep Kumar Padhi; Girish Kumar Pati; Ayaskanta Singh; Bijay Misra; Debasis Misra; Sanjib Kumar Kar; Manas Kumar Panigrahi; Chudamani Meher; Omprakash Agrawal; Niranjan Rout; Kaumudee Pattnaik; Pallavi Bhuyan; Pramila Kumari Mishra; Shivaram Prasad Singh
Journal:  Indian J Clin Biochem       Date:  2016-09-03

9.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

Authors:  Kevin M Korenblat; Elisa Fabbrini; B Selma Mohammed; Samuel Klein
Journal:  Gastroenterology       Date:  2008-01-30       Impact factor: 22.682

Review 10.  Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes.

Authors:  Iliana Doycheva; Niraj Patel; Michael Peterson; Rohit Loomba
Journal:  J Diabetes Complications       Date:  2013-01-09       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.